X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Aventis: Looking healthier - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Oct 23, 2004

    Aventis: Looking healthier

    Performance Summary
    MNC pharma major Aventis, recently announced its 3QCY04 and 9mCY04 results. During 3QCY04, the topline grew by 13.1% YoY while the bottomline grew by 63% YoY. For the first nine months of the year, while the topline growth was 11.2%, the bottomline grew by an even more impressive 73.7% as compared to same period last year. Cost cutting measures has seen the company improving its operating margins by an astonishing 1120 basis points during the third quarter.

    (Rs m) 3QCY03 3QCY04 Change 9mCY03 9mCY04 Change
    Net sales 1,628 1,841 13.1% 4,788 5,369 12.1%
    Expenditure 1,264 1,223 -3.2% 3,852 3,831 -0.5%
    Operating profit (EBDITA) 364 618 69.8% 936 1,538 64.3%
    Operating profit margin (%) 22.4% 33.6%   19.5% 28.6%  
    Other income 61 82 34.4% 129 158 22.5%
    Interest - -   0 -  
    Depreciation 38 42 10.5% 133 126 -5.3%
    Exceptional Item 5 -   70 68  
    Profit before tax 382 658 72.3% 1,002 1,638 63.5%
    Tax 121 233 92.6% 320 559 74.7%
    Profit after tax/(loss) 261 425 62.8% 682 1,079 58.2%
    Net profit margin (%) 16.0% 23.1%   14.2% 20.1%  
    No. of shares (m) 23.0 23.0   23.0 23.0  
    Diluted earnings per share (Rs)*       59.2 62.5  
    P/E ratio (x)         13.6  
    (* annualised)            

    What’s the company’s business?
    Aventis Pharma - the 50% subsidiary of Aventis SA, France is the 2nd largest pharma MNC in India with a turnover of over Rs 7 bn (CY03). It is the 6th largest domestic player with a market share of 2.9%. Aventis has relatively few but very strong brands in the country. Over the years, it has progressively transformed itself into a company catering to the chronic (diabetes, CVS) and critical-care therapeutic segments. Apart from catering to the Indian markets, the company supplies bulk drugs to its parent, which constituted about 26% of the company’s sales in 1HCY04. Recently, the parent has decided to merge with another France based pharma company, Sanofi, thus making it part of one of the largest pharma conglomerates.

    What has driven performance in 2QCY04?
    Exports lead the charge: Sales growth in 3QCY04 was largely driven by strong performance on the exports front. It grew by 63% on the back of demand arising from higher supply to its parent company. The company’s products are sold in Russia and CIS countries as well. Decent performance in domestic market (6% growth) continued in this quarter too. The company’s growth has been in line with the domestic market in last few quarters and it is likely to maintain this momentum going forward. The major growth drivers were the key brands such as Amaryl (17%), Cardace (10%), Clexane (24%) and Targocid (18%) (estimates).

    Operating level boost: The operating profit grew by 70% in the quarter under review. Lower raw material cost and other expenses as a percentage of sales were largely responsible for the margin improvement. The increasing share of outsourcing (export sales) and better management of manufacturing expenses has also led to higher margins. Better product mix, which was possible due to strong focus on strategic brands also played its part in margin improvement.

    Cost Structure 9mCY03 9mCY04 Growth
    Raw Material 2,443 2,427 -1%
    as % of sales 51.0% 45.2%  
    Staff Cost 407 465 14%
    as % of sales 8.5% 8.7%  
    Others 1,002 939 -6%
    as % of sales 20.9% 17.5%  
    Total 3,852 3,831 -1%

    Over the last few quarters
    As evident from the graph below, the company’s performance has improved with every passing quarter. While sales growth in the last six quarters was very much dependent on the domestic market, the real kicker in 1QCY04 has come from exports, which grew by 16% YoY. However, on the operational front, the company has managed to maintain margins (are superior to the industry) due to its focused business interest.

    What to expect?
    At Rs 851, the stock is trading at 15.6x annualized 9mCY04 earnings. Apart from the domestic market, which seems to be doing pretty well, Aventis has an opportunity to scale up the contribution from exports in the future i.e. outsourcing to the parent. In fact Aventis is the only major MNC pharma company, which has a clear-cut strategy on out-sourcing. The company has managed to grow the export side significantly and is likely to go up further, as the company is investing in capacities to capitalize on this opportunity. Also, there is significant opportunity for the company in terms of launching new products from its parent's portfolio once the new patent regime comes into force few months from new.

     

     

    Equitymaster requests your view! Post a comment on "Aventis: Looking healthier". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

    Aug 21, 2017

    Most Indians who cannot find jobs, look at becoming self-employed.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

    Aug 22, 2017

    Post demonetisation, a cut in bank savings deposits rates was in the offing.

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    SANOFI INDIA SHARE PRICE


    Aug 24, 2017 01:11 PM

    TRACK SANOFI INDIA

    • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    SANOFI INDIA - NATCO PHARMA COMPARISON

    Compare Company With Charts

    COMPARE SANOFI INDIA WITH

    MARKET STATS